CDT Equity (CDT) Share-based Compensation (2023 - 2026)
CDT Equity's (CDT) quarterly Share-based Compensation came in at $1.4 million in Q1 2026, up 498.29% YoY from $234000.0 in Q1 2025, and up 177.78% on a QoQ basis from -$1.8 million in Q4 2025.
CDT Equity (CDT) Share-based Compensation (2023 - 2026) Analysis & Trends
CDT Equity (CDT) has 4 years of Share-based Compensation data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Share-based Compensation rose 498.29% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 314.07% YoY) and the FY2025 annual result came in at $2.8 million, up 16.67% from the prior year.
- Share-based Compensation advanced to $1.4 million in Q1 2026, from -$1.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.1 million in Q2 2024 to a low of -$1.8 million in Q4 2025.
- A 4-year average of $740545.5 and a median of $431000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation slumped 2947.92% — and 2026, when it jumped 498.29%.
- Tracing CDT's Share-based Compensation over 4 years: stood at $48000.0 in 2023, then tumbled by 2947.92% to -$1.4 million in 2024, then slumped by 31.68% to -$1.8 million in 2025, then jumped by 177.78% to $1.4 million in 2026.
- The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), -$1.8 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | CDT Equity | 1.61 Mn | 1.61 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Jun 30, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | -1.80 Mn |
| Dec 31, 2025 | -1.80 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 234,000.00 |
| Mar 31, 2025 | 234,000.00 |
| Dec 31, 2024 | -1.37 Mn |
| Dec 31, 2024 | -1.37 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 431,000.00 |
| Mar 31, 2024 | 431,000.00 |